International Journal of Cardiology 176 (2014) 1309–1311
Contents lists available at ScienceDirect
International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard
Letter to the Editor
Removal of an intracardiac lost port-A catheter utilizing a simple low-cost method Placido Romeo a, Giuseppe Mario Calvagna b,⁎, Marco Giunta a, Felice Vito Vitale c, Salvatore Patanè b a b c
Radiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy Cardiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy UOC Oncologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy
a r t i c l e
i n f o
Article history: Received 17 June 2014 Accepted 27 July 2014 Available online 2 August 2014 Keywords: Cancer Cardio-oncology Foreign intravascular bodies Interventistic radiology Port-A catheter Transvenous extraction
The intravenous port-A catheters are widely used for long-term central venous access [1–3] in cancer patients [1,4–46]. Spontaneous fracture and migration of implanted port catheters is a known complication and necessitates immediate removal [1–46]. Transvenous extraction technique of foreign intravascular bodies and lead catheters is commonly performed [46–71]. We describe the removal of an intracardiac lost port-A catheter utilizing a simple method with a material normally available in the laboratories of interventional radiology. In May 2010 we observed a patient with a malfunctioning left subclavian port-A catheter. Chest X-ray examination revealed the presence of spontaneous fracture and migration of implanted lead in the right atrium, with apexes positioned inside the right ventricular cavity. We proceeded to remove it because of the arrhythmias that were determined and of its potential infectious risk. The technical difficulty of the case was due to the fact that the systems to handle type goose-necks are easily usable when one of the heads of the catheters is in an accessible position and catchable with the handle. The intravascular placement of both catheter heads makes it more difficult to retrieve the system as well as it triggered
ventricular arrhythmias that were not tolerated by the patient. In such situations and in the unavailability of retrieval sophisticated systems (Allison fragment grasper and vascular retrieval forceps), we tried to mobilize the port-A-cath by bending it with a pigtail catheter (Fig. 1 Panel A) which have a femoral vein access to attempt to bring one apex. In the case in question this attempt was unsuccessful because of the higher resistance offered by the catheter to the traction. To avoid repeating the procedure under more and more ‘adequate availability’ of materials we tried a combined approach with double femoral venous access. From the first venous access a modified pigtail catheter without a tip (umbrella handle like) was inserted, and by the second venous access a catheter snare (Fig. 1 (Panel B)) was inserted. Fig. 1 (Panel C) shows a chest-radiography with the dislodged port-A-cath. The umbrella handle like catheter blocked the lost catheter while the snare captured the tip of the modified pigtail then pulled both catheters at the same time. This procedure allowed finally the release of one tip of the lost catheter and then held it in the vena cava with the umbrella handle like catheter, to recover it with the snare, and take it out through one of the two used venous access sites. Fig. 2 (Panels A, B, and C) shows removal phases. The procedure has been successfully completed without complications. This simple low cost method may be useful in selected situations without the use of expensive and not always easily available specialized material. Conflict of interest The authors report no relationships that could be construed as a conflict of interest. Author contributions Placido Romeo described Fig. 2 and prepared Fig. 2. Giuseppe Mario Calvagna prepared Fig. 1. Marco Giunta described Fig. 1. Felice Vito Vitale prepared the References. Salvatore Patanè wrote the manuscript. Acknowledgments
⁎ Corresponding author at: Cardiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy. Tel.: +39 3474800260. E-mail address: [email protected] (G.M. Calvagna).
http://dx.doi.org/10.1016/j.ijcard.2014.07.156 0167-5273/© 2014 Elsevier Ireland Ltd. All rights reserved.
The authors of this manuscript have certified that they adhere to the statement of ethical publishing as appears in International Journal of Cardiology.
1310
P. Romeo et al. / International Journal of Cardiology 176 (2014) 1309–1311
Fig. 1. (Panel A): pigtail catheter. (Panel B): snare catheter. (Panel C): chest-radiography with the dislodged port-A-cath.
Fig. 2. (Panels A, B, and C): removal phases.
References [1] Choksy P, Zaidi SS, Kapoor D. Removal of intracardiac fractured port-A catheter utilizing an existing forearm peripheral intravenous access site in the cath lab. J Invasive Cardiol Feb 2014;26(2):75–6. [2] Lin MC, Chang TK, Fu YC, Jan SL. A magic port-A-cath. JACC Cardiovasc Interv Mar 2013;6(3):e17–8. [3] Mousa AY, Gill G, Aburahma AF. New trick for removal of intravascular retained foreign body: a case report and review of literature. Vasc Endovascular Surg Jan 2014; 48(1):55–7. [4] Scott JM, Jones LW, Hornsby WE, et al. Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training. Int J Cardiol Feb 1 2014;171(2):e50–1. [5] Claridge S, Chakrabarti A, Greaves K, Boos CJ. Successful use of trastuzumab following cardiac resynchronisation therapy. Int J Cardiol Jun 20 2013; 166(2):e33–4. [6] Lotrionte M, Palazzoni G, Abbate A, et al. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation) randomized pilot study. Int J Cardiol Aug 10 2013;167(3):1055–7. [7] Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol Sep 1 2013;167(5):2306–10. [8] Wang KL, Liu CJ, Chao TF, et al. Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis. Int J Cardiol Sep 1 2013;167(5): 2162–6. [9] Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol May 10 2013; 165(2):355–7. [10] Budaj-Fidecka A, Kurzyna M, Fijałkowska A, et al. ZATPOL Registry Investigators. Inhospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL registry data. Int J Cardiol Oct 9 2013;168(4):3543–9. [11] Pugliatti P, Donato R, Di Bella G, Carerj S, Patanè S. Contrast-enhancing right atrial thrombus in cancer patient. Int J Cardiol May 15 2014;173(3):e35–7. [12] Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol Oct 15 2013;168(6):5465–7.
[13] Jurczak W, Szmit S, Sobociński M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol Oct 15 2013;168(6):5212–7. [14] Cardioncology Lestuzzi C. Oncocardiology. Are we barking up the wrong tree? Int J Cardiol Jul 31 2013;167(2):307–9. [15] Pugliatti P, Donato R, Zito C, Carerj S, Patanè S. Cardio inhibitory vasovagal syncope in a cancer patient. Int J Cardiol Jun 15 2014;174(2):e64-5. [16] Pugliatti P, De Gregorio C, Patanè S. The chance finding of echocardiographic complications of infective endocarditis. Int J Cardiol Nov 29 2012;161(3):e50–1. [17] Patanè S. HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014 Aug 2;176(3):1085–8. [18] Elkina Y, Palus S, Tschirner A, et al. Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. Int J Cardiol Dec 10 2013;170(2):160–6. [19] Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Int J Cardiol Oct 9 2013;168(4):3527–31. [20] Palus S, von Haehling S, Flach VC, et al. Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. Int J Cardiol Oct 9 2013;168(4):3412–8. [21] Avbelj V, Trobec R. A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope. Int J Cardiol Jul 1 2013;166(3):e59–61. [22] Jang WJ, Yim HR, Lee SH, Park SJ, Kim JS, On YK. Prognosis after tilt training in patients with recurrent vasovagal syncope. Int J Cardiol Oct 9 2013;168(4):4264–5. [23] Loh KP, Ogunneye O. Malignant cardioinhibitory vasovagal syncope — an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int J Cardiol Apr 15 2013;164(3):e38–9. [24] Patanè S, Marte F. Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system. Eur Heart J May 2009;30(10):1169–70. [25] Arcopinto M, Cella CA, Wesolowski R, et al. Primary prevention of cancer-related thrombosis: Special focus on ambulatory patients. Int J Cardiol May 15 2014; 173(3):583–4. [26] Patanè S. Breast cancer treatment cardioprotective strategies: the King is naked. J Am Heart Assoc 2014 Published July 22,2014 http://www.jaha.ahajournals.org/content/3/2/e000665/reply. [27] Cardinale D. A new frontier: cardio-oncology. Cardiologia Sep 1996;41(9):887–91. [28] Patanè S, Marte F. Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol Jan 7 2011;146(1):e20–2.
P. Romeo et al. / International Journal of Cardiology 176 (2014) 1309–1311 [29] Patanè S, Marte F. Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario. Int J Cardiol May 29 2009;134(3):e147–9. [30] Patanè S. Prostate-specific antigen kallikrein and the heart. World J Cardiol Dec 31 2009;1(1):23–5. [31] Scarano M, Pezzuoli F, Torrisi G, Calvagna GM, Patanè S. Cardiovascular implantable electronic device infective endocarditis. Int J Cardiol May 15 2014;173(3):e38–9. [32] Patanè S. Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res Apr 2014;7(3):369–71. [33] Patanè S. Is there a need for bacterial endocarditis prophylaxis in patients undergoing Gastrointestinal Endoscopy? J Cardiovasc Transl Res Apr 2014;7(3):372–4. [34] Patanè S. A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis. Int J Cardiol Jun 14 2012;157(3):448–9. [35] Patanè S. Cardiotoxicity: cisplatin and long term cancer survivors. Int J Cardiol Jul 15 2014;175(1):201–2. [36] Patanè S. A challenge in cardiology: the oncosurgery. Int J Cardiol Jun 15 2014; 174(2):411–2. [37] Patanè S. Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer. Curr Med Res Opin Jun 2014;26:1–2 http://informahealthcare.com. [38] Patanè S, Marte F, Sturiale M, Dattilo G. ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses. Int J Cardiol Apr 14 2011;148(2):e31–3. [39] Ozkanlar Y, Aktas MS, Turkeli M, et al. Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity. Int J Cardiol May 15 2014;173(3):519–21. [40] Patanè S. Cardiotoxicity: Anthracyclines and long term cancer survivors. Int J Cardiol 2014;176(3):1329–31. [41] Patanè S. Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies. J Card Fail Jun 2014;20(6):456–7. [42] Patanè S. Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014 Aug 2;176(3): 1309–11. [43] Patanè S. ERBB1/EGFR and ERBB2 (HER2/neu) — Targeted therapies in cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014 Aug 2;176(3): 1301–3. [44] Conti E, Romiti A, Musumeci MB, et al. Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. Int J Cardiol Sep 10 2013;167(6):2421–9. [45] Rateesh S, Luis SA, Luis CR, Hughes B, Nicolae M. Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol Mar 15 2014;172(2):e331–3. [46] Kurisu S, Iwasaki T, Ishibashi K, Mitsuba N, Dohi Y, Kihara Y. Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients. Int J Cardiol Sep 1 2013;167(5):2335–7. [47] Calvagna GM, Patanè S. Severe staphylococcal sepsis in patient with permanent pacemaker. Int J Cardiol Apr 1 2014;172(3):e498–501. [48] Ward C, Henderson S, Metcalfe NH. A short history on pacemakers. Int J Cardiol Nov 15 2013;169(4):244–8. [49] Ahmed S, Ungprasert P, Srivali N, Ratanapo S, Cheungpasitporn W, Chongnarungsin D. Lead perforation: an uncommon cause of chest pain in a patient with pacemaker. Int J Cardiol Sep 1 2013;167(5):e113–4. [50] Calvagna GM, Ceresa F, Patanè S. Subcutaneous implantable cardioverter–defibrillator in a young woman. Int J Cardiol Aug 1 2014;175(2):e30–2. [51] Calvagna GM. Recall, malfunzionamenti e infezioni in portatori di PM/ICD. Possono condizionare le scelte clinico-interventistiche e la qualità della vita? GIAC 2010; 13(3–4):217–22. [52] Calvagna GM. Progressivo malfunzionamento di elettrocatetere da stimolazione cardiaca permanente secondario a processo infettivo asintomatico. GIAC 2012; 15(1):51–4.
1311
[53] Calvagna GM, Curatolo S, La Greca S, Evola R. Sepsi Stafilococciche in pazienti portatori di PM e\o ICD: Dal trattamento antibiotico all'intervento di Rimozione Transvenosa Manuale. G Ital Aritmol Cardiostim Marzo 2010;13(1):1. [54] Calvagna GM, Mangano A, Evola R. Infezioni su estremita' distali degli elettrocateteri da stimolazione cardiaca permanente rimossi mediante tecnica transvenosa manuale:casistica dal 2002 al 2007 presso centro unico dedicato. G Ital Aritmol Cardiostim 2008;4:65–8. [55] Woodhouse JB, Uberoi R. Techniques for intravascular foreign body retrieval. Cardiovasc Intervent Radiol Aug 2013;36(4):888–97. [56] Kawata H, Patel J, McGarry T, et al. Obese female patients have higher rates of lead dislodgement after ICD or CRT-D implantation. Int J Cardiol Apr 1 2014;172(3): e522–4. [57] Calvagna GM, Evola R. Complicanze non infettive o malfunzionamenti in pazienti portatori di PM e/o ICD: importanza della rimozione transvenosa. G Ital Aritmol Cardiostim 2009;12(2):69–78. [58] Calvagna GM, Patanè S, Romeo P, Ceresa F, Sansone F, Patanè F. Embolization and retrieval of an anchoring sleeve during transvenous lead extraction. Int J Cardiol May 15 2014;173(3):e42–4. [59] Calvagna GM, Foti R, Lisi M, Evola R. Rimozione transvenosa manuale di elettrocateteri da Pacemaker e\o ICD malfunzionanti o infetti mediante tecnica transvenosa manuale: Esperienza di unico centro regionale dedicato (anni 2002–2007). G Ital Aritmol Cardiostim 2007;4:30–5. [60] Calvagna GM, Evola R, Scardace G, Valsecchi S. Single-operator experience with a mechanical approach for removal of pacing and implantable defibrillator leads. Europace Nov 2009;11(11):1505–9. [61] Calvagna GM, Evola R, Scardace G, Valsecchi S. Successful removal of a jugular implantable defibrillator lead with mechanical single-sheath technique. Pacing Clin Electrophysiol Sep 2012;35(9):e258–60. [62] Calvagna GM, Evola R, Valsecchi S. A complication of pacemaker lead extraction: pulmonary embolization of an electrode fragment. Europace 2010;12:613. [63] Calvagna GM, Romeo P, Ceresa F, Valsecchi S. Transvenous retrieval of foreign objects lost during cardiac device implantation or revision: a 10-year experience. Pacing Clin Electrophysiol Jul 2013;36(7):892–7. [64] Calvagna GM, Torrisi G, Giuffrida C, Patanè S. Pacemaker, implantable cardioverter defibrillator, CRT, CRT-D, psychological difficulties and quality of life. Int J Cardiol Jun 15 2014;174(2):378–80. [65] Ceresa F, Sansone F, Patanè S, Calvagna GM, Patanè F. Superior vena cava obstruction as late complication of biventricular pacemaker implantation: Surgical replacement of the malfunctioning previous leads. Int J Cardiol 2014;176(3):e83–5. [66] Calvagna GM, Patanè S. Transvenous pacemaker lead extraction in infective endocarditis. Int J Cardiol 2014 Jul 12;176(3):1312–4. [67] Rodriguez Y, Garisto J, Carrillo RG. Management of cardiac device-related infections: a review of protocol-driven care. Int J Cardiol Jun 5 2013;166(1):55–60 [Review]. [68] Cho H, Kim M, Uhm JS, Pak HN, Lee MH, Joung B. Transvenous pacemaker lead removal in pacemaker lead endocarditis with large vegetations: a report of two cases. Korean Circ J Mar 2014;44(2):118–21. [69] Singh N, Langer V, Chadha DS, et al. Percutaneous removal of transvenous pacemaker leads using an extraction device. Med J Armed Forces India Jul 2013;69(3):291–3. [70] Bongiorni MG, Soldati E, Zucchelli G, et al. Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches: high success rate and safety in more than 2000 leads. Eur Heart J 2008;29:2886–93. [71] Sohal M, Williams SE, Arujuna A, et al. The current practice and perception of cardiac implantable electronic device transvenous lead extraction in the UK. Europace Jun 2013;15(6):865–70.
Contents lists available at ScienceDirect
International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard
Letter to the Editor
Removal of an intracardiac lost port-A catheter utilizing a simple low-cost method Placido Romeo a, Giuseppe Mario Calvagna b,⁎, Marco Giunta a, Felice Vito Vitale c, Salvatore Patanè b a b c
Radiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy Cardiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy UOC Oncologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy
a r t i c l e
i n f o
Article history: Received 17 June 2014 Accepted 27 July 2014 Available online 2 August 2014 Keywords: Cancer Cardio-oncology Foreign intravascular bodies Interventistic radiology Port-A catheter Transvenous extraction
The intravenous port-A catheters are widely used for long-term central venous access [1–3] in cancer patients [1,4–46]. Spontaneous fracture and migration of implanted port catheters is a known complication and necessitates immediate removal [1–46]. Transvenous extraction technique of foreign intravascular bodies and lead catheters is commonly performed [46–71]. We describe the removal of an intracardiac lost port-A catheter utilizing a simple method with a material normally available in the laboratories of interventional radiology. In May 2010 we observed a patient with a malfunctioning left subclavian port-A catheter. Chest X-ray examination revealed the presence of spontaneous fracture and migration of implanted lead in the right atrium, with apexes positioned inside the right ventricular cavity. We proceeded to remove it because of the arrhythmias that were determined and of its potential infectious risk. The technical difficulty of the case was due to the fact that the systems to handle type goose-necks are easily usable when one of the heads of the catheters is in an accessible position and catchable with the handle. The intravascular placement of both catheter heads makes it more difficult to retrieve the system as well as it triggered
ventricular arrhythmias that were not tolerated by the patient. In such situations and in the unavailability of retrieval sophisticated systems (Allison fragment grasper and vascular retrieval forceps), we tried to mobilize the port-A-cath by bending it with a pigtail catheter (Fig. 1 Panel A) which have a femoral vein access to attempt to bring one apex. In the case in question this attempt was unsuccessful because of the higher resistance offered by the catheter to the traction. To avoid repeating the procedure under more and more ‘adequate availability’ of materials we tried a combined approach with double femoral venous access. From the first venous access a modified pigtail catheter without a tip (umbrella handle like) was inserted, and by the second venous access a catheter snare (Fig. 1 (Panel B)) was inserted. Fig. 1 (Panel C) shows a chest-radiography with the dislodged port-A-cath. The umbrella handle like catheter blocked the lost catheter while the snare captured the tip of the modified pigtail then pulled both catheters at the same time. This procedure allowed finally the release of one tip of the lost catheter and then held it in the vena cava with the umbrella handle like catheter, to recover it with the snare, and take it out through one of the two used venous access sites. Fig. 2 (Panels A, B, and C) shows removal phases. The procedure has been successfully completed without complications. This simple low cost method may be useful in selected situations without the use of expensive and not always easily available specialized material. Conflict of interest The authors report no relationships that could be construed as a conflict of interest. Author contributions Placido Romeo described Fig. 2 and prepared Fig. 2. Giuseppe Mario Calvagna prepared Fig. 1. Marco Giunta described Fig. 1. Felice Vito Vitale prepared the References. Salvatore Patanè wrote the manuscript. Acknowledgments
⁎ Corresponding author at: Cardiologia Ospedale San Vincenzo - Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina (Messina), Italy. Tel.: +39 3474800260. E-mail address: [email protected] (G.M. Calvagna).
http://dx.doi.org/10.1016/j.ijcard.2014.07.156 0167-5273/© 2014 Elsevier Ireland Ltd. All rights reserved.
The authors of this manuscript have certified that they adhere to the statement of ethical publishing as appears in International Journal of Cardiology.
1310
P. Romeo et al. / International Journal of Cardiology 176 (2014) 1309–1311
Fig. 1. (Panel A): pigtail catheter. (Panel B): snare catheter. (Panel C): chest-radiography with the dislodged port-A-cath.
Fig. 2. (Panels A, B, and C): removal phases.
References [1] Choksy P, Zaidi SS, Kapoor D. Removal of intracardiac fractured port-A catheter utilizing an existing forearm peripheral intravenous access site in the cath lab. J Invasive Cardiol Feb 2014;26(2):75–6. [2] Lin MC, Chang TK, Fu YC, Jan SL. A magic port-A-cath. JACC Cardiovasc Interv Mar 2013;6(3):e17–8. [3] Mousa AY, Gill G, Aburahma AF. New trick for removal of intravascular retained foreign body: a case report and review of literature. Vasc Endovascular Surg Jan 2014; 48(1):55–7. [4] Scott JM, Jones LW, Hornsby WE, et al. Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training. Int J Cardiol Feb 1 2014;171(2):e50–1. [5] Claridge S, Chakrabarti A, Greaves K, Boos CJ. Successful use of trastuzumab following cardiac resynchronisation therapy. Int J Cardiol Jun 20 2013; 166(2):e33–4. [6] Lotrionte M, Palazzoni G, Abbate A, et al. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation) randomized pilot study. Int J Cardiol Aug 10 2013;167(3):1055–7. [7] Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol Sep 1 2013;167(5):2306–10. [8] Wang KL, Liu CJ, Chao TF, et al. Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis. Int J Cardiol Sep 1 2013;167(5): 2162–6. [9] Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol May 10 2013; 165(2):355–7. [10] Budaj-Fidecka A, Kurzyna M, Fijałkowska A, et al. ZATPOL Registry Investigators. Inhospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL registry data. Int J Cardiol Oct 9 2013;168(4):3543–9. [11] Pugliatti P, Donato R, Di Bella G, Carerj S, Patanè S. Contrast-enhancing right atrial thrombus in cancer patient. Int J Cardiol May 15 2014;173(3):e35–7. [12] Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol Oct 15 2013;168(6):5465–7.
[13] Jurczak W, Szmit S, Sobociński M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol Oct 15 2013;168(6):5212–7. [14] Cardioncology Lestuzzi C. Oncocardiology. Are we barking up the wrong tree? Int J Cardiol Jul 31 2013;167(2):307–9. [15] Pugliatti P, Donato R, Zito C, Carerj S, Patanè S. Cardio inhibitory vasovagal syncope in a cancer patient. Int J Cardiol Jun 15 2014;174(2):e64-5. [16] Pugliatti P, De Gregorio C, Patanè S. The chance finding of echocardiographic complications of infective endocarditis. Int J Cardiol Nov 29 2012;161(3):e50–1. [17] Patanè S. HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014 Aug 2;176(3):1085–8. [18] Elkina Y, Palus S, Tschirner A, et al. Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. Int J Cardiol Dec 10 2013;170(2):160–6. [19] Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Int J Cardiol Oct 9 2013;168(4):3527–31. [20] Palus S, von Haehling S, Flach VC, et al. Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. Int J Cardiol Oct 9 2013;168(4):3412–8. [21] Avbelj V, Trobec R. A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope. Int J Cardiol Jul 1 2013;166(3):e59–61. [22] Jang WJ, Yim HR, Lee SH, Park SJ, Kim JS, On YK. Prognosis after tilt training in patients with recurrent vasovagal syncope. Int J Cardiol Oct 9 2013;168(4):4264–5. [23] Loh KP, Ogunneye O. Malignant cardioinhibitory vasovagal syncope — an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int J Cardiol Apr 15 2013;164(3):e38–9. [24] Patanè S, Marte F. Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system. Eur Heart J May 2009;30(10):1169–70. [25] Arcopinto M, Cella CA, Wesolowski R, et al. Primary prevention of cancer-related thrombosis: Special focus on ambulatory patients. Int J Cardiol May 15 2014; 173(3):583–4. [26] Patanè S. Breast cancer treatment cardioprotective strategies: the King is naked. J Am Heart Assoc 2014 Published July 22,2014 http://www.jaha.ahajournals.org/content/3/2/e000665/reply. [27] Cardinale D. A new frontier: cardio-oncology. Cardiologia Sep 1996;41(9):887–91. [28] Patanè S, Marte F. Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol Jan 7 2011;146(1):e20–2.
P. Romeo et al. / International Journal of Cardiology 176 (2014) 1309–1311 [29] Patanè S, Marte F. Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario. Int J Cardiol May 29 2009;134(3):e147–9. [30] Patanè S. Prostate-specific antigen kallikrein and the heart. World J Cardiol Dec 31 2009;1(1):23–5. [31] Scarano M, Pezzuoli F, Torrisi G, Calvagna GM, Patanè S. Cardiovascular implantable electronic device infective endocarditis. Int J Cardiol May 15 2014;173(3):e38–9. [32] Patanè S. Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res Apr 2014;7(3):369–71. [33] Patanè S. Is there a need for bacterial endocarditis prophylaxis in patients undergoing Gastrointestinal Endoscopy? J Cardiovasc Transl Res Apr 2014;7(3):372–4. [34] Patanè S. A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis. Int J Cardiol Jun 14 2012;157(3):448–9. [35] Patanè S. Cardiotoxicity: cisplatin and long term cancer survivors. Int J Cardiol Jul 15 2014;175(1):201–2. [36] Patanè S. A challenge in cardiology: the oncosurgery. Int J Cardiol Jun 15 2014; 174(2):411–2. [37] Patanè S. Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer. Curr Med Res Opin Jun 2014;26:1–2 http://informahealthcare.com. [38] Patanè S, Marte F, Sturiale M, Dattilo G. ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses. Int J Cardiol Apr 14 2011;148(2):e31–3. [39] Ozkanlar Y, Aktas MS, Turkeli M, et al. Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity. Int J Cardiol May 15 2014;173(3):519–21. [40] Patanè S. Cardiotoxicity: Anthracyclines and long term cancer survivors. Int J Cardiol 2014;176(3):1329–31. [41] Patanè S. Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies. J Card Fail Jun 2014;20(6):456–7. [42] Patanè S. Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014 Aug 2;176(3): 1309–11. [43] Patanè S. ERBB1/EGFR and ERBB2 (HER2/neu) — Targeted therapies in cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol 2014 Aug 2;176(3): 1301–3. [44] Conti E, Romiti A, Musumeci MB, et al. Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. Int J Cardiol Sep 10 2013;167(6):2421–9. [45] Rateesh S, Luis SA, Luis CR, Hughes B, Nicolae M. Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol Mar 15 2014;172(2):e331–3. [46] Kurisu S, Iwasaki T, Ishibashi K, Mitsuba N, Dohi Y, Kihara Y. Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients. Int J Cardiol Sep 1 2013;167(5):2335–7. [47] Calvagna GM, Patanè S. Severe staphylococcal sepsis in patient with permanent pacemaker. Int J Cardiol Apr 1 2014;172(3):e498–501. [48] Ward C, Henderson S, Metcalfe NH. A short history on pacemakers. Int J Cardiol Nov 15 2013;169(4):244–8. [49] Ahmed S, Ungprasert P, Srivali N, Ratanapo S, Cheungpasitporn W, Chongnarungsin D. Lead perforation: an uncommon cause of chest pain in a patient with pacemaker. Int J Cardiol Sep 1 2013;167(5):e113–4. [50] Calvagna GM, Ceresa F, Patanè S. Subcutaneous implantable cardioverter–defibrillator in a young woman. Int J Cardiol Aug 1 2014;175(2):e30–2. [51] Calvagna GM. Recall, malfunzionamenti e infezioni in portatori di PM/ICD. Possono condizionare le scelte clinico-interventistiche e la qualità della vita? GIAC 2010; 13(3–4):217–22. [52] Calvagna GM. Progressivo malfunzionamento di elettrocatetere da stimolazione cardiaca permanente secondario a processo infettivo asintomatico. GIAC 2012; 15(1):51–4.
1311
[53] Calvagna GM, Curatolo S, La Greca S, Evola R. Sepsi Stafilococciche in pazienti portatori di PM e\o ICD: Dal trattamento antibiotico all'intervento di Rimozione Transvenosa Manuale. G Ital Aritmol Cardiostim Marzo 2010;13(1):1. [54] Calvagna GM, Mangano A, Evola R. Infezioni su estremita' distali degli elettrocateteri da stimolazione cardiaca permanente rimossi mediante tecnica transvenosa manuale:casistica dal 2002 al 2007 presso centro unico dedicato. G Ital Aritmol Cardiostim 2008;4:65–8. [55] Woodhouse JB, Uberoi R. Techniques for intravascular foreign body retrieval. Cardiovasc Intervent Radiol Aug 2013;36(4):888–97. [56] Kawata H, Patel J, McGarry T, et al. Obese female patients have higher rates of lead dislodgement after ICD or CRT-D implantation. Int J Cardiol Apr 1 2014;172(3): e522–4. [57] Calvagna GM, Evola R. Complicanze non infettive o malfunzionamenti in pazienti portatori di PM e/o ICD: importanza della rimozione transvenosa. G Ital Aritmol Cardiostim 2009;12(2):69–78. [58] Calvagna GM, Patanè S, Romeo P, Ceresa F, Sansone F, Patanè F. Embolization and retrieval of an anchoring sleeve during transvenous lead extraction. Int J Cardiol May 15 2014;173(3):e42–4. [59] Calvagna GM, Foti R, Lisi M, Evola R. Rimozione transvenosa manuale di elettrocateteri da Pacemaker e\o ICD malfunzionanti o infetti mediante tecnica transvenosa manuale: Esperienza di unico centro regionale dedicato (anni 2002–2007). G Ital Aritmol Cardiostim 2007;4:30–5. [60] Calvagna GM, Evola R, Scardace G, Valsecchi S. Single-operator experience with a mechanical approach for removal of pacing and implantable defibrillator leads. Europace Nov 2009;11(11):1505–9. [61] Calvagna GM, Evola R, Scardace G, Valsecchi S. Successful removal of a jugular implantable defibrillator lead with mechanical single-sheath technique. Pacing Clin Electrophysiol Sep 2012;35(9):e258–60. [62] Calvagna GM, Evola R, Valsecchi S. A complication of pacemaker lead extraction: pulmonary embolization of an electrode fragment. Europace 2010;12:613. [63] Calvagna GM, Romeo P, Ceresa F, Valsecchi S. Transvenous retrieval of foreign objects lost during cardiac device implantation or revision: a 10-year experience. Pacing Clin Electrophysiol Jul 2013;36(7):892–7. [64] Calvagna GM, Torrisi G, Giuffrida C, Patanè S. Pacemaker, implantable cardioverter defibrillator, CRT, CRT-D, psychological difficulties and quality of life. Int J Cardiol Jun 15 2014;174(2):378–80. [65] Ceresa F, Sansone F, Patanè S, Calvagna GM, Patanè F. Superior vena cava obstruction as late complication of biventricular pacemaker implantation: Surgical replacement of the malfunctioning previous leads. Int J Cardiol 2014;176(3):e83–5. [66] Calvagna GM, Patanè S. Transvenous pacemaker lead extraction in infective endocarditis. Int J Cardiol 2014 Jul 12;176(3):1312–4. [67] Rodriguez Y, Garisto J, Carrillo RG. Management of cardiac device-related infections: a review of protocol-driven care. Int J Cardiol Jun 5 2013;166(1):55–60 [Review]. [68] Cho H, Kim M, Uhm JS, Pak HN, Lee MH, Joung B. Transvenous pacemaker lead removal in pacemaker lead endocarditis with large vegetations: a report of two cases. Korean Circ J Mar 2014;44(2):118–21. [69] Singh N, Langer V, Chadha DS, et al. Percutaneous removal of transvenous pacemaker leads using an extraction device. Med J Armed Forces India Jul 2013;69(3):291–3. [70] Bongiorni MG, Soldati E, Zucchelli G, et al. Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches: high success rate and safety in more than 2000 leads. Eur Heart J 2008;29:2886–93. [71] Sohal M, Williams SE, Arujuna A, et al. The current practice and perception of cardiac implantable electronic device transvenous lead extraction in the UK. Europace Jun 2013;15(6):865–70.
